← All trials
NCT05086692
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2021
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- Oct 21, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medicenna Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Biliary Tract Neoplasms
- Urinary Bladder Neoplasms
- Basal Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Gallbladder Neoplasms
- Hamartoma
- Carcinoma, Hepatocellular
- Melanoma
- Mesothelioma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Skin Neoplasms
- Stomach Neoplasms
- Uterine Neoplasms
- Colorectal Neoplasms
- Carcinoma, Merkel Cell
- Endometrial Neoplasms
- Cholangiocarcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.